×

Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy

HEIDELBERG, Germany, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CMO, Jens-Peter Marschner, will present at the symposium titled "Emerging Approaches in Cancer Immunotherapy" in New York City on Monday, February 29 at 12:10-12:40 pm Eastern Standard Time. The symposium will be presented as part of the New York Academy of Sciences' Cancer and Signaling Discussion Group, which provides a forum for scientists from academia, industry, and government, as well as other stakeholders, to come together to explore cutting-edge topics in the field. A live webcast of Affimed's presentation will be available through the New York Academy of Sciences' website at www.nyas.org.

About Affimed N.V.

Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.

CONTACT: IR Contact: Caroline Stewart, Head of IR Phone: +1 347394 6793 E-Mail: IR@affimed.com or c.stewart@affimed.com Media Contact: Anca Alexandru, Head of Communications Phone: +49 6221 64793341 E-Mail: a.alexandru@affimed.com

Source:Affimed Therapeutics